Since the finding by Johnson and Ascher (1987) demonstrating that glycine enhances
electrophysiological responses mediated by N-methyl-D-aspartate (NMDA) b

The neurotransmitter glutamate activates several classes of metabotropic receptor and three
major types of ionotropic receptor – α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (…

β‐amyloid (Aβ) is widely accepted to be one of the major pathomechanisms underlying
Alzheimer's disease (AD), although there is presently lively debate regarding the relative roles of …

There is increasing evidence for the involvement of glutamate‐mediated neurotoxicity in the
pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N‐…

The authors provide an extensive review of new data related to the role of glutamate in CNS
disorders, describing new aspects in glutamate and glutamatergic receptors-NMDA …

The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer’s
disease is finding increasingly more acceptance in the scientific community. Central to this …

This review describes the preclinical mechanisms that may underlie the increased therapeutic
benefit of combination therapy—with the N-methyl-d-aspartate receptor antagonist, …

l-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of
Parkinson's Disease. A model of LID has recently been described in rats with unilateral 6-…

Metabotropic glutamate receptor type 5 (mGluR5) modulates dopamine and glutamate
neurotransmission at central synapses. In this study, we addressed the role of mGluR5 in l‐DOPA…

A series of novel tricyclic pyrido-phthalazine-dione derivatives was tested for antagonistic
effects at the strychnine-insensitive modulatory site of the N-methyl-d-aspartate (NMDA) …